The cholesterol uptake regulator PCSK9 promotes and is a therapeutic target in APC/KRAS-mutant colorectal cancer

Therapeutic targeting of KRAS-mutant colorectal cancer (CRC) is an unmet need. Here, we show that Proprotein Convertase Subtilisin/Kexin type 9 (PSCK9) promotes APC/KRAS-mutant CRC and is a therapeutic target. Using CRC patient cohorts, isogenic cell lines and transgenic mice, we identify that de no...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Chi Chun, Wu, Jian-Lin, Ji, Fenfen, Kang, Wei, Bian, Xiqing, Chen, Huarong, Chan, Lam-Shing, Luk, Simson Tsz Yat, Tong, Samuel, Xu, Jiaying, Zhou, Qiming, Liu, Dabin, Su, Hao, Gou, Hongyan, Cheung, Alvin Ho-Kwan, To, Ka Fai, Cai, Zongwei, Shay, Jerry W., Yu, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270407/
https://www.ncbi.nlm.nih.gov/pubmed/35803966
http://dx.doi.org/10.1038/s41467-022-31663-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270407/
https://www.ncbi.nlm.nih.gov/pubmed/35803966
http://dx.doi.org/10.1038/s41467-022-31663-z

Ejemplares similares